José M. Climent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
José M. Climent has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jose Maria Azorin
Miguel Hernández University of Elche
2 shared publications - Andrés Úbeda
University of Alicante
1 shared publication Carmen Rodríguez-Ruiz
Department of Physical Medicine and Rehabilitation, Hospital San Jaime, Torrevieja, Spain
1 shared publication- Daniel Planelles
Brain-Machine Interface Systems Lab, Miguel Hernández University of Elche, Av. de la Universidad, S/N, Elche, 03202, Spain.
1 shared publication Diego Gómez-Gallego
Department of Physical Medicine and Rehabilitation, Hospital General Universitario, Alicante, Spain
1 shared publication- Eduardo Iáñez
Brain-Machine Interface Systems Lab, Miguel Hernández University of Elche, Elche, Spain
1 shared publication
Latest Publications
- 7 July 2020
- Published by Elsevier in Rehabilitación
- Vol. 55 (1) , 79-80
La evolución del número de elección MIR en rehabilitación
- 7 July 2020
- Published by Elsevier in Rehabilitación
- Vol. 55 (1) , 79-80
La evolución del número de elección MIR en rehabilitación
- Open Access
- 17 October 2015
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 12 (1) , 1-16
Using a brain-machine interface to control a hybrid upper limb exoskeleton during rehabilitation of patients with neurological conditions
As a consequence of the increase of cerebro-vascular accidents, the number of people suffering from motor disabilities is raising. Exoskeletons, Functional Electrical Stimulation (FES) devices and Brain-Machine Interfaces (BMIs) could be combined for rehabilitation purposes in order to improve therapy outcomes. In this work, a system based on a hybrid upper limb exoskeleton is used for neurological rehabilitation. Reaching movements are supported by the passive exoskeleton ArmeoSpring and FES. The movement execution is triggered by an EEG-based BMI. The BMI uses two different methods to interact with the exoskeleton from the user’s brain activity. The first method relies on motor imagery tasks classification, whilst the second one is based on movement intention detection. Three healthy users and five patients with neurological conditions participated in the experiments to verify the usability of the system. Using the BMI based on motor imagery, healthy volunteers obtained an average accuracy of 82.9 ± 14.5 %, and patients obtained an accuracy of 65.3 ± 9.0 %, with a low False Positives rate (FP) (19.2 ± 10.4 % and 15.0 ± 8.4 %, respectively). On the other hand, by using the BMI based on detecting the arm movement intention, the average accuracy was 76.7 ± 13.2 % for healthy users and 71.6 ± 15.8 % for patients, with 28.7 ± 19.9 % and 21.2 ± 13.3 % of FP rate (healthy users and patients, respectively). The accuracy of the results shows that the combined use of a hybrid upper limb exoskeleton and a BMI could be used for rehabilitation therapies. The advantage of this system is that the user is an active part of the rehabilitation procedure. The next step will be to verify what are the clinical benefits for the patients using this new rehabilitation procedure.
- 17 October 2015
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 12 (1) , 1-16
Open AccessUsing a brain-machine interface to control a hybrid upper limb exoskeleton during rehabilitation of patients with neurological conditions
As a consequence of the increase of cerebro-vascular accidents, the number of people suffering from motor disabilities is raising. Exoskeletons, Functional Electrical Stimulation (FES) devices and Brain-Machine Interfaces (BMIs) could be combined for rehabilitation purposes in order to improve therapy outcomes. In this work, a system based on a hybrid upper limb exoskeleton is used for neurological rehabilitation. Reaching movements are supported by the passive exoskeleton ArmeoSpring and FES. The movement execution is triggered by an EEG-based BMI. The BMI uses two different methods to interact with the exoskeleton from the user’s brain activity. The first method relies on motor imagery tasks classification, whilst the second one is based on movement intention detection. Three healthy users and five patients with neurological conditions participated in the experiments to verify the usability of the system. Using the BMI based on motor imagery, healthy volunteers obtained an average accuracy of 82.9 ± 14.5 %, and patients obtained an accuracy of 65.3 ± 9.0 %, with a low False Positives rate (FP) (19.2 ± 10.4 % and 15.0 ± 8.4 %, respectively). On the other hand, by using the BMI based on detecting the arm movement intention, the average accuracy was 76.7 ± 13.2 % for healthy users and 71.6 ± 15.8 % for patients, with 28.7 ± 19.9 % and 21.2 ± 13.3 % of FP rate (healthy users and patients, respectively). The accuracy of the results shows that the combined use of a hybrid upper limb exoskeleton and a BMI could be used for rehabilitation therapies. The advantage of this system is that the user is an active part of the rehabilitation procedure. The next step will be to verify what are the clinical benefits for the patients using this new rehabilitation procedure.
- Open Access
- 6 June 2013
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 33 (7) , 497-503
Treatment of Morton Neuroma with Botulinum Toxin A: A Pilot Study
Background and Objective Morton neuroma is a common cause of metatarsalgia of neuropathic origin. Systematic reviews suggest that insufficient studies have been performed on the efficacy of the different treatments available. OnabotulinumtoxinA has shown a degree of usefulness in other conditions associated with neuropathic pain. The aim of this study was to investigate the therapeutic potential of onabotulinumtoxinA in Morton neuroma. Patients and Methods We present an open-label, pilot study with 17 consecutive patients with Morton neuroma and pain of more than 3 months’ duration that had not responded to conservative treatment with physical measures or corticosteroid injection. Patients received one onabotulinumtoxinA injection in the area of the neuroma. The main outcome measure was the variation in the pain on walking evaluated using a visual analogue scale (VAS) before treatment and at 1 and 3 months after treatment. The secondary outcome was the change in foot function, which was assessed using the Foot Health Status Questionnaire. Results In the overall group, the mean initial VAS score on walking was 7. This mean score had fallen to 4.8 at 1 month after treatment and to 3.7 at 3 months. Twelve patients (70.6 %) reported an improvement in their pain and five patients (29.4 %) reported no change; exacerbation of the pain did not occur in any patient. Improvements were also observed in two of the dimensions of the Foot Health Status Questionnaire: foot pain, which improved from a mean of 38.88 before treatment to 57 at 3 months, and foot function, which improved from a mean of 42.27 before treatment to 59.9 at 3 months. Clinical variables including age, sex, site and size of the lesion, standing activity, weekly duration of walking, footwear, foot type and footprint had no influence on the outcome. No adverse effects were reported. Conclusions In this pilot study, injection with onabotulinumtoxinA was shown to be of possible usefulness to relieve the pain and improve function in Morton neuroma. This finding opens the door to further clinical research.
- 6 June 2013
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 33 (7) , 497-503
Open AccessTreatment of Morton Neuroma with Botulinum Toxin A: A Pilot Study
Background and Objective Morton neuroma is a common cause of metatarsalgia of neuropathic origin. Systematic reviews suggest that insufficient studies have been performed on the efficacy of the different treatments available. OnabotulinumtoxinA has shown a degree of usefulness in other conditions associated with neuropathic pain. The aim of this study was to investigate the therapeutic potential of onabotulinumtoxinA in Morton neuroma. Patients and Methods We present an open-label, pilot study with 17 consecutive patients with Morton neuroma and pain of more than 3 months’ duration that had not responded to conservative treatment with physical measures or corticosteroid injection. Patients received one onabotulinumtoxinA injection in the area of the neuroma. The main outcome measure was the variation in the pain on walking evaluated using a visual analogue scale (VAS) before treatment and at 1 and 3 months after treatment. The secondary outcome was the change in foot function, which was assessed using the Foot Health Status Questionnaire. Results In the overall group, the mean initial VAS score on walking was 7. This mean score had fallen to 4.8 at 1 month after treatment and to 3.7 at 3 months. Twelve patients (70.6 %) reported an improvement in their pain and five patients (29.4 %) reported no change; exacerbation of the pain did not occur in any patient. Improvements were also observed in two of the dimensions of the Foot Health Status Questionnaire: foot pain, which improved from a mean of 38.88 before treatment to 57 at 3 months, and foot function, which improved from a mean of 42.27 before treatment to 59.9 at 3 months. Clinical variables including age, sex, site and size of the lesion, standing activity, weekly duration of walking, footwear, foot type and footprint had no influence on the outcome. No adverse effects were reported. Conclusions In this pilot study, injection with onabotulinumtoxinA was shown to be of possible usefulness to relieve the pain and improve function in Morton neuroma. This finding opens the door to further clinical research.
- 1 January 2013
- Published by Springer Nature
- p. 489-493
Error Potential Detection to Assist Movement Intention Decoding in Stroke Patients
- 1 January 2013
- Published by Springer Nature
- p. 489-493
Error Potential Detection to Assist Movement Intention Decoding in Stroke Patients